How to Diagnose G6PD Deficiency
Diagnose G6PD deficiency by measuring quantitative G6PD enzyme activity normalized to hemoglobin (G6PD/Hb ratio in U/g Hb) using spectrophotometry or automated analyzers, with molecular genetic testing reserved for cases with borderline results, recent transfusions, or heterozygous females with normal enzyme activity but high clinical suspicion.
Primary Diagnostic Approach
Quantitative Enzyme Activity Testing
The gold standard is quantitative G6PD enzyme activity measurement normalized to hemoglobin concentration (expressed as U/g Hb). This can be performed using:
- Automated analyzers (e.g., BS-2800M) with superior performance 1
- Spectrophotometric methods as the traditional reference standard 2
- Point-of-care devices (e.g., STANDARD G6PD Test) for rapid screening with sensitivity/specificity of 100%/97% 3
Diagnostic thresholds for non-neonates:
- Deficient: < 2.31 U/g Hb (males and females)
- Intermediate females: 2.31-6.17 U/g Hb 1
Diagnostic thresholds for neonates:
- Deficient: < 4.14 U/g Hb
- Intermediate: 4.14-11.03 U/g Hb 1
Sample Preparation Requirements
Critical: Enzyme assays performed on whole blood will produce falsely elevated results and miss the diagnosis 4. You must purify red blood cells by either:
- Leukocyte filtration (preferred, reduces WBC to 5%)
- Buffy coat removal (acceptable alternative, reduces WBC to 15%)
Timing Considerations
After blood transfusion: Wait at least 50 days post-transfusion for reliable results. At 50 days, donor RBC contamination is only 6-12%, which should not cause a missed diagnosis 4. If clinical urgency requires earlier testing, interpret results with extreme caution as false negatives are likely.
Sample stability: Test within 4 hours at room temperature or within 48 hours if refrigerated at 4°C. Do NOT freeze samples at -20°C as this significantly reduces G6PD activity 1.
Special Populations and Pitfalls
Heterozygous Females
This is where standard enzyme testing frequently fails. Flow cytometry significantly outperforms spectrophotometry in detecting heterozygous females, with an 87.5% detection rate versus only 39-52% for standard methods 5, 2. The automated G6PDH method also shows superior performance (87.5% detection) compared to conventional methods 1.
Why heterozygous females are missed: X-chromosome inactivation creates a mosaic population of normal and deficient RBCs. If the proportion of normal cells is sufficient, total enzyme activity may appear normal or borderline despite clinically significant deficiency.
Reticulocytosis
High reticulocyte counts can mask G6PD deficiency because young RBCs contain higher enzyme levels. When you encounter low-normal G6PD activity in a patient with high reticulocyte count and clinical suspicion, calculate the PK/HK ratio or G6PD/HK ratio to account for cell age 4. A drastically reduced ratio confirms deficiency even when absolute G6PD activity appears normal.
High White Blood Cell Counts
Elevated WBC counts cause overestimation of G6PD activity in both reference assays and point-of-care tests 3. This is why proper RBC purification is non-negotiable.
Macrocytosis as a Clinical Clue
59.6% of "healthy" individuals with macrocytosis (MCV > 100 fL) have G6PD deficiency 6. The mechanism: chronic low-grade hemolysis triggers compensatory bone marrow hyperplasia, increasing the proportion of young, larger RBCs. In endemic areas, unexplained macrocytosis should prompt G6PD testing.
When to Add Molecular Genetic Testing
Proceed to molecular analysis in these specific scenarios 5:
- Reduced enzyme activity requiring variant identification for family counseling
- Recent blood transfusion making enzyme testing unreliable
- Heterozygous females with normal/borderline enzyme activity but strong clinical suspicion
- Borderline or inconclusive enzyme results that don't fit the clinical picture
- Preconception counseling or assisted reproductive technologies
Molecular testing identifies the specific G6PD variant and achieves 91.35% diagnostic accuracy when integrated with enzyme testing 5.
Emerging Technologies
Flow cytometry quantifies the percentage of G6PD-deficient RBCs at the single-cell level, making it particularly valuable for heterozygous females 2. However, it shows false negatives in sickle cell disease patients, so interpret cautiously in this population.